Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report by Gurmit Gill et al.
CASE REPORT Open Access
Interaction of interferon alpha therapy with
thyroid function tests in the management
of hepatitis C: a case report
Gurmit Gill1*, Hammad Bajwa1, Peter Strouhal2 and Harit N. Buch1
Abstract
Background: Interferon alpha is a widely used therapeutic agent in the treatment of hepatitis C virus infection.
Clinical thyroid disease is seen in nearly 15 % of patients receiving interferon alpha for hepatitis C virus infection.
The mechanism of thyroid dysfunction with interferon alpha is either autoimmune or inflammatory. We report a
case of young woman who developed biphasic thyroid dysfunction posing a diagnostic challenge, while receiving
interferon alpha treatment for hepatitis C virus infection.
Case presentation: A 29-year-old, Caucasian woman with type 1 diabetes and hepatitis C virus infection was referred
with hyperthyroidism, while she was at 17 weeks of a planned 24-week course of interferon alpha therapy. A laboratory
investigation revealed a thyroid stimulation hormone level of 0.005 mU/L (0.350–4.94), free thyroxine of 45.6 pmol/L
(9.0–19.0) and free tri-iodothyronine of 12.6 pmol/L (2.6–5.7). She had a mild neutropenia and alanine aminotransferase
at double the reference value. Her thyroid peroxidase antibody level was 497 ku/L (<5.6) and thyroid inhibitory factor 7
IU/L (>1.8 iu/l is positive). Thyroid scintigraphy with technetium99 scan confirmed a normal-sized thyroid gland with
diffuse but normal overall uptake. A diagnosis of interferon alpha-triggered autoimmune hyperthyroidism as opposed
to an inflammatory thyroiditis was made. She was offered radioactive iodine therapy, as thionamides were considered
inappropriate in view of her liver disease and mild neutropenia. Due to our patient’s personal circumstances,
radioactive iodine therapy was delayed by 8 weeks and her thyrotoxic symptoms were controlled with beta-
blockers alone. A repeat thyroid function test, 4 weeks post treatment with interferon alpha, indicated spontaneous
conversion to hypothyroidism with a thyroid stimulation hormone level of 100 mU/L, free thyroxine of 5.2 pmol/L and
free tri-iodothyronine of 1.7 pmol/L. She subsequently received levothyroxine for 4 months only and had remained
euthyroid for the last 3 months without any treatment.
Conclusions: Initial investigations favored the autoimmune nature of hyperthyroidism but follow-up of the case,
interestingly, was more consistent with inflammatory thyroiditis. We propose that this can be explained either on the
basis of autoimmune subacute thyroiditis or a change in the nature of thyroid stimulation hormone receptor antibody
production from stimulating-type to blocking-type antibodies, with disappearance of the latter on discontinuation of
interferon alpha.
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Background
Interferon alpha is a widely used therapeutic agent and
is employed in the treatment of hepatitis C virus infec-
tion (HCV) [1]. However, up to 15 % of patients receiv-
ing interferon alpha for HCV infection can develop
clinical thyroid disease [2]. The precise relationship be-
tween interferon alpha therapy and the development of
thyroid pathology can be complex and the mechanism
of thyroid dysfunction should be assessed in each patient
prior to initiation of treatment. We present a case where
therapeutic decisions were difficult to make in view of
the unusual course of thyroid dysfunction.
Case presentation
A 29-year-old, Caucasian woman with HCV (genotype 3)
was referred from a gastroenterology clinic with hyperthy-
roidism, diagnosed on routine thyroid function testing.
She had a 23-year history of type 1 diabetes, which was
complicated by nephropathy and proliferative retinopathy
and for which she was on a multiple-dose insulin regime.
She reported a 6-kg weight loss, heat intolerance, and
amenorrhoea in the preceding 3 months. On examination,
she had mild positional tremor but no other clinical fea-
tures of hyperthyroidism. She did not have a palpable goi-
ter or thyroid eye disease. At the time of referral she had
been receiving interferon alpha therapy (180 mcg Pegasys®
once weekly by subcutaneous administration) for 17
weeks of a planned 24-week course of treatment, in
addition to 800 mg Copegus daily by oral administration.
A laboratory investigation revealed a thyroid stimulation
hormone (TSH) level of 0.005 mU/L (reference range
0.350–4.94), free thyroxine (FT4) of 45.6 pmol/L (9.0–
19.0) and free tri-iodothyronine (FT3) of 12.6 pmol/L
(2.6–5.7). Her hemoglobin was 127 g/L (115–165), white
cell count 1.8 × 10E9/L (4.0–11.0), platelets 118 × 10E9/L
(150–450) neutrophils 1.0 × 10E9/L (2.0–7.5), bilirubin 7
umol/L (0–20), alkaline phosphatase 63 iu/L (30–130),
alanine transaminase 120 iu/L (<55), albumin 32 g/L
(35–50) and she had normal renal function. Her thyroid
peroxidase (TPO) antibody level was 497 ku/L (<5.6)
and thyroid inhibitory factor was 7 IU/L (<1.0 iu/L is
negative, 1.0–1.8 iu/L is borderline, >1.8 iu/L is posi-
tive). A thyroid scintigraphy with technetium99 scan
(Radionucleotide (RN) scan) revealed a normal-sized
thyroid gland with diffuse but normal overall uptake
but not suppressed (Figs. 1 and 2).
On the basis of the above investigations she was sus-
pected to have interferon alpha-triggered hyperthyroidism
related to a diffuse autoimmune process as opposed to an
inflammatory thyroiditis. In view of persistent hyperthy-
roidism over subsequent weeks and the likelihood of
the autoimmune process to continue after withdrawal
of interferon alpha, it was decided to initiate specific
therapy to control hyperthyroidism. Thionamides were
not considered appropriate in view of her history of liver
disease and suppressed neutrophil count and a decision
was made to administer radioiodine (RAI) therapy for
which she was appropriately counselled. However, due to
our patient’s personal circumstances, RAI therapy was de-
layed by 8 weeks and her hyperthyroid symptoms were
controlled with beta-blockers. During this period she
completed her 24-week interferon alpha therapy and when
she presented for her pre-RAI assessment she had been
off interferon for 4 weeks. A repeat thyroid function test
indicated spontaneous conversion to hypothyroidism with
a TSH level of 100 mU/L, FT4 of 5.2 pmol/L, and FT3 of
1.7 pmol/L. Repeat biochemical testing 3 weeks later
confirmed persistent hypothyroidism and, in view of her
significant symptoms, she was commenced on thyroxine
replacement. She remained euthyroid on 100 mcg thyrox-
ine over the next 4 months. At the end of this period
thyroxine was withdrawn, and when last seen 3 months
later she had remained euthyroid off thyroxine and was
hepatitis C virus free.
Discussion
Interferon alpha is the cornerstone of therapy for hepatitis
C infection (HCV) [1, 3, 4]. It can achieve a sustained
virological response in up to 50 % of patients and hence
has been widely used as therapeutic agent in patients with
HCV infection. However, new-onset thyroid dysfunction
is a major side effect and prevalence rates of up to 15 %
have been reported [2].
The mechanism of thyroid dysfunction with interferon
alpha is either autoimmune or inflammatory [5]. In one
series of 321 patients, of the 10 patients who developed
hyperthyroidism, 6 had an autoimmune presentation
while the other 4 patients had destructive thyroiditis [6].
Most other series report a fairly even distribution
Fig. 1 Radionuclide images
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between the prevalence of the two types of thyroid
dysfunction [7].
The diverse effects of interferon alpha on the immune
system that leads to its therapeutic actions are also re-
sponsible for the development of autoimmunity. It binds
to interferon alpha receptors, which are transmembrane
glycoproteins-containing cytoplasmic domains. As a re-
sult it activates various signaling pathways, including the
Janus kinase/signal transducer and activator of tran-
scription (JAK-STAT) pathway, the proto-oncogene Crk
(Crk) pathway, the insulin receptor signaling (IRS) signal-
ing pathway and the mitogen-activated protein (MAP)
kinase pathway, which in turn leads to activation of a large
number of interferon-stimulated genes (ISGs) including
cytokine and adhesion molecule genes [8–10]. Interferon
alpha induced increased expression of MHC class 1 anti-
gens on the thyroid cells is another possible mechanism of
stimulating autoimmunity. Interferon alpha also shifts the
immune response to a type 1 helper (Th1)-mediated
pattern [11, 12], resulting in the production of potent
pro-inflammatory cytokines including interferon gamma
(IFN-γ) and interleukin-2 (IL-2), thereby stimulating auto-
immunity [13, 14]. Other possible mechanisms include
stimulation of interleukin-6 (IL-6) release, enhancement
of the activity of neutrophils, lymphocytes, macrophages
and natural killer (NK) cells, all of which can potentially
contribute to development of autoimmunity-mediated in-
flammatory response [15, 16]. It has also been demon-
strated from molecular studies that HCV proteins could
independently impact and contribute to autoimmune
thyroid dysfunction [17] through the binding of HCV gly-
coproteins to CD8 receptors expressed on thyroid cells
and inducing a cascade of signaling pathways leading to
interleukin-8 (IL-8) release.
Forty percent of patients who develop thyroid dysfunc-
tion while on interferon alpha therapy become thyroid
antibody positive, and antibodies prior to initiation of
interferon alpha therapy have a positive predictive value
of 67 % for the development of thyroid dysfunction [7].
Patients who progress to hyperthyroidism demonstrate a
significant rise in thyroid antibody levels [18]. This has
led to the recommendation that thyroid antibody testing
should be undertaken prior to initiation of interferon
alpha therapy. Other predictors include female gender
and lower FT3 levels [7, 19].
Inflammatory non-autoimmune thyroiditis is usually a
destructive process occurring within the gland. It results
from the direct effect of interferon alpha on thyroid cells
with inhibition of TSH-induced gene expression of thyro-
globulin, TPO, and sodium iodide symporter as shown in
various laboratory studies [20].
The clinical course of autoimmune thyroid dysfunc-
tion is similar to that of Graves’ disease and patients re-
quire standard anti-thyroid management especially as, in
most cases, withdrawal of interferon alpha does not lead
to resolution of hyperthyroidism [6, 13, 21] and patients
remain thyroid antibody-positive [6, 13, 21]. Use of anti-
thyroid drugs has to be carefully considered in view of
the hepatic dysfunction and neutropenia that accompan-
ies the use of interferon alpha. On the other hand,
Fig. 2 Radionuclide images
Gill et al. Journal of Medical Case Reports  (2016) 10:253 Page 3 of 5
inflammatory non-autoimmune thyroid dysfunction is
clinically characterized by three phases, that is sudden
onset of hyperthyroidism, followed by a hypothyroid
state and eventually resolution and normalization of thy-
roid function, which can take several weeks to months
[22]. As spontaneous resolution is expected, anti-thyroid
therapy is not required for management of hyperthyroid-
ism. Beta-blockers are used for symptomatic benefit and,
during the hypothyroid phase, patients may require thy-
roxine with planned withdrawal after 3–6 months. Five
percent of patients have permanent hypothyroidism and
patients who have complete recovery remain susceptible
to recurrence on being re-exposed to interferon alpha.
In view of its impact on the management strategy, it
is important to identify the mechanism of interferon
alpha-induced thyroid dysfunction with appropriate in-
vestigations. Thyroid antibodies, more specifically TSH
receptor antibodies and radionuclide uptake scans are
helpful in making this distinction. Positive antibodies
with non-suppressed radionuclide uptake suggest an
autoimmune process while negative antibodies with sup-
pressed radionuclide uptake would support inflammatory
thyroiditis.
In summary, the case emphasizes the need to assess the
risk of development of thyroid dysfunction prior to com-
mencement of interferon alpha in patients with HCV in-
fection and to monitor such patients closely clinically and
biochemically. It also highlights the importance of appro-
priate investigations to elucidate the possible mechanism
of thyroid dysfunction prior to formulating management
plans, although an unexpected pattern of thyroid dysfunc-
tion is occasionally encountered, as in our patient.
Conclusions
Our patient had an unexpected course of hyperthyroid-
ism. She had several features to suggest an autoimmune
process with her background of autoimmune type 1
diabetes; positive TSH receptor antibodies and a non-
suppressed radionuclide uptake scan, undertaken during
significant hyperthyroidism. While waiting for definitive
management in the form of RAI therapy, she spontan-
eously reverted to hypothyroidism, which was transient,
and our patient eventually staged a full recovery of thyroid
function. This sequence of thyroid dysfunction was sug-
gestive of destructive thyroiditis rather than diffuse
autoimmune hyperthyroidism. The explanation for the
discrepancy between investigation results and the clinical
course was unclear. Positive antibodies and biphasic
thyroid dysfunction can be explained on the basis of
autoimmune subacute thyroiditis. However this is not
supported by radionuclide scan, which would be expected
to show suppressed uptake in inflammatory thyroiditis of
any etiology. A change in iodine status has been linked to
fluctuating and varying thyroid status in patients on
interferon alpha [23]. However our patient had been resid-
ing in the UK for a number of years and there were no
other factors to suspect this possibility. A more likely ex-
planation is a change in the nature of antibody production
from stimulating-type to blocking-type antibodies, with
disappearance of the latter on discontinuation of inter-
feron alpha. This was difficult to confirm, as assays for
identifying subtypes of TSH receptor antibodies are not
readily available. The changing nature of antibodies has
been observed anecdotally in other situations of induced
autoimmune process. A similar course was also reported
in a series of four patients following the use of alemtuzu-
mab for multiple sclerosis, with one of the patients devel-
oping hypothyroidism soon after the initial presentation
with hyperthyroidism [24].
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